About us
Overview
Our strategy
Our leadership
How we’re funded
Our history
What we do
Overview
Our science
Therapeutics
Diagnostics development
Partnering with us
Funding, projects and partnerships
Available technologies
LifeArc Ventures
IP management and tech transfer
Policy and public affairs
Translational Challenges
Overview
Motor Neuron Disease
Chronic Respiratory Infection
Global Health
Antimicrobial Resistance
Neglected Tropical Diseases
Emerging Viral Threats
Rare Disease
Childhood Cancer
News and events
News
Events
Careers
Overview
Benefits and rewards
Early careers
Current vacancies
Contact us
Search
Toggle Menu
Search
Search
Search
Refine results
Content Type
Careers
Case Studies
Funding Calls
Other Technologies
Pages
People
Posts
Projects
Publications
Therapeutics
Topic
Company updates
Motor neuron disease
Chronic respiratory infection
Global health
Rare disease
Childhood cancer
Neurodegeneration
Policy and public affairs
Technology transfer
Our science
Ventures
MRC Technology forms alliance with world leading translational research centres to accelerate global drug development
Post
21 January 2013
Read more
: MRC Technology forms alliance with world leading translational research centres to accelerate global drug development
Mount Sinai School of Medicine and MRC Technology to collaborate on monoclonal antibody production and humanization
Post
2 April 2012
Read more
: Mount Sinai School of Medicine and MRC Technology to collaborate on monoclonal antibody production and humanization
LifeArc, Dstl and CDRD collaborate to identify antibacterial drug targets
Post
27 June 2017
Read more
: LifeArc, Dstl and CDRD collaborate to identify antibacterial drug targets
Industry leaders launch HealthHub 21 to scale-up digital solutions for faster & more accessible care
Post
21 April 2021
Read more
: Industry leaders launch HealthHub 21 to scale-up digital solutions for faster & more accessible care
LifeArc negotiates exclusive licence deal with Nemysis Limited for oral iron supplement technology
Post
20 July 2017
Read more
: LifeArc negotiates exclusive licence deal with Nemysis Limited for oral iron supplement technology
£1 million awarded to develop cutting-edge therapies for motor neuron disease
Post
24 January 2023
Read more
: £1 million awarded to develop cutting-edge therapies for motor neuron disease
KQ Labs data driven health accelerator announces its first exit, as Glamorous AI is acquired by X-Chem Inc
Post
1 November 2021
Read more
: KQ Labs data driven health accelerator announces its first exit, as Glamorous AI is acquired by X-Chem Inc
LifeArc announces seed fund investment in start-up GyreOx
Post
17 March 2020
Read more
: LifeArc announces seed fund investment in start-up GyreOx
LifeArc and AUTM forge international partnership to provide training for scholars in technology transfer
Post
30 August 2017
Read more
: LifeArc and AUTM forge international partnership to provide training for scholars in technology transfer
LifeArc and DEBRA Austria launch £2.5m funding call for repurposing therapies for Epidermolysis Bullosa
Post
10 July 2023
Read more
: LifeArc and DEBRA Austria launch £2.5m funding call for repurposing therapies for Epidermolysis Bullosa
Cancer Research UK, Lifearc and Ono Pharma Form Cancer Immunotherapy Alliance
Post
27 March 2019
Read more
: Cancer Research UK, Lifearc and Ono Pharma Form Cancer Immunotherapy Alliance
LifeArc co-leads £6 million funding in DJS Antibodies
Post
22 December 2020
Read more
: LifeArc co-leads £6 million funding in DJS Antibodies
Previous Page
1
…
4
5
6
7
8
…
10
Next Page
Close Modal
WordPress development by
Andy White
using
PorterWP